Phenamacril is a
Fusarium
-specific fungicide used
for
Fusarium
head blight management. The target of
phenamacril is FgMyo1, the sole class I myosin in
Fusarium
graminearum
. The point mutation S217L in FgMyo1 is
responsible for the high resistance of
F. graminearum
to phenamacril. Recent structural studies have shown that phenamacril
binds to the 50 kDa cleft of the FgMyo1 motor domain, forming extensive
interactions, including a hydrogen bond between the cyano group of
phenamacril and the hydroxyl group of S217. Here, we produced FgMyo1
IQ2
, a truncated FgMyo1 composed of the motor domain and two
IQ motifs complexed with the
F. graminearum
calmodulin in insect Sf9 cells. Phenamacril potently inhibited both
the basal and the actin-activated ATPase activities of FgMyo1
IQ2
, with an IC
50
in a micromolar range. S217 mutations
of FgMyo1
IQ2
substantially increased the IC
50
of phenamacril. S217T or S217L each increased the IC
50
of phenamacril for ∼60-fold, while S217A only increased the
IC
50
for ∼4-fold. These results indicate that the
hydroxyl group of S217 plays an important, but nonessential role in
phenamacril binding and that the bulky side chain at the position
217 sterically hinders phenamacril binding. On the other hand, S217P,
which might alter the local conformation of the phenamacril-binding
site, completely abolished the phenamacril inhibition. Because the
cyano group of phenamacril does not form discernible interactions
with FgMyo1 other than the nonessential hydrogen bond with the S217
hydroxyl group, we propose the cyano group of phenamacril as a key
modification site for the development of novel fungicides.